We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Blood Test Could Cut Hospital Stays for Children with Cancer

By LabMedica International staff writers
Posted on 21 Mar 2022

High temperatures are common in children undergoing treatment for cancer due to their lowered immune system. More...

The commonest approach is to keep children in hospital for up to a week while antibiotics are administered in case the fever is a symptom of a serious infection like sepsis. A new blood test could help to safely cut hospital stays for children with cancer who develop a fever, according to a new study.

The study, by researchers from the University of York (York, UK) and Hull York Medical School (York, UK) reveals the blood test can help doctors to distinguish between children whose fever is a sign of serious illness and those who are safe to go home. The results of the study, which involved 28 children with cancer, show that using the blood test in combination with a new protocol to identify children that are safe to go home, cuts their average stay in hospital down to two days, with some able to leave in as little as eight hours. The researchers believe that this change will make an enormous difference to children with cancer and their families, easing mental health and financial burdens. The test diagnoses serious infections by looking at levels of the biomarker procalcitonin in the blood. Those children with low levels often had their antibiotics stopped more quickly and went home earlier.

"Frequent fevers are a distressing and sometimes life-threatening complication of childhood cancer. Our study shows that procalcitonin blood tests could make a big difference to children who don’t have a serious infection, allowing them to go home earlier to be with their families, cutting unnecessary treatment with antibiotics and reducing an already intense mental and physical toll," said Dr. Bob Phillips from the Centre for Reviews and Dissemination at the University of York and Hull York Medical School. "These promising results and the willingness of families to take part in this research mean we can now apply for further funding in order to carry out a large-scale study."

Related Links:
University of York 
Hull York Medical School 


New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Collection and Transport System
PurSafe Plus®
New
Hemodynamic System Monitor
OptoMonitor
New
Blood Glucose Test Strip
AutoSense Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Left is the original cell image and right is same cell image zoomed in and rendered in the special imaging software (Photo courtesy of FIU)

Brain Inflammation Biomarker Detects Alzheimer’s Years Before Symptoms Appear

Alzheimer’s disease affects millions globally, but patients are often diagnosed only after memory loss and other symptoms appear, when brain damage is already extensive. Detecting the disease much earlier... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.